

DAFTAR PUSTAKA

1. Asther *et al.* WHO classification of tumours online. female genital tumours (5th edition). endometriosis and related conditions// endometriosis and derived tumours. international agency for research on cancer. 2025.
2. Huang *et al.* Worldwide burden, risk factors, and temporal trends of ovarian cancer: a global study. cancers. 2022.
3. Cabasag *et al.* ovarian cancer today and tomorrow: a global assessment by world region and human development index using globocan 2020. int j cancer. 2022.
4. Li *et al.* Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021. journal of hematology and oncology. 2025.
5. Bray *et al.* Global cancer statistic 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 18 countries. ca cancer j clin. 2024.
6. Budiana *et al.* Ovarian cancer: pathogenesis and current recommendations for prophylactic surgery. j turks ger gynecol assoc. 2019.
7. Kemenkes RI. rencana kanker nasional 2024-2034: strategi indonesia dalam upaya melawan kanker. kementerian kesehatan republik indonesia. 2024.
8. Badan Registrasi Kanker Perhimpunan Dokter Spesialis Patologi Anatomi. Kanker di indonesia tahun 2011 data histopatologik, direktorat jendral pelayanan medik departemen kesehatan ri, jakarta, yayasan kanker indonesia. 2011.
9. Engin *et al.* Endometriosis and adenomiosis: global perspective across the lifespan. springer. 2022.
10. IJ Rowlands *et al.* Global epidemiological data on endometriosis. spinger nature link. 2022.
11. WHO. Endometriosis: world health organization fact-sheets. available online at <https://www.who.int/news-room/fact-sheets/detail/endometriosis>.2025.
12. Rahmioglu *et al.* Endometriosis: disease mechanism and health disparities. bulletin of the WHO. 2024.
13. Wikipedia. HIF1A. Wikipedia the free encyclopaedia. 2025. available at https://en.wikipedia.org/wiki/hif1a?utm_source=chatgpt.com
14. Dai *et al.* Hypoxia and the endometrium: an indispensable role for hif-1 α as theurapeutic strategies. redox biology. elsevier. 2024.
15. Chen *et al.* Advances in research on malignant transformation of endometriosis-associated ovarian cancer. mini review. frontiers in oncology. 2024.
16. Asis *et al.* Research: association hypoxia inducible factors-1 alpha (hif-1 α) levels and epithelial ovarian cancer (eoc). indonesian journal of obstetric and gynecology science. makassar. 2023. volume 6 nomor 1.
17. Lee *et al.* Over expression of hypoxia-inducible factor 1-alpha in ovarian clear cell carcinoma. gynecologic oncologic. 2007. p311-317.
18. Varga *et al.* Research: predictive factors of endometriosis progression into ovarian cancer. journal of ovarian research. 2022. 15:5.

19. Andreou *et al.* Prognostic factors influencing survival in ovarian cancer patients: a 10-year retrospective study. *cancers*. 2023
20. Chen *et al.* Review: new insights about endometriosis- associated ovarian cancer: pathogenesis, risk factors, prediction and diagnosis and treatment. *frontiers in oncology*. 2024.
21. Hablase *et al.* The “road” to malignant transformation from endometriosis to endometriosis-associated ovarian cancer (eaocs): an mtor-centred review. *cancers*. MDPI. 2024.
22. WHO. Female genital tumours. who classifications of tumours 5th edition. international agency for research on cancer. 2020. volume 4.
23. Priyanto *et al.* Analysis of the malignancy risk of endometriosis and ovarian cancer related to endometriosis-associated ovarian cancer: a histopathological review and genetic mutation. research article. *journal of south asian federation of obstetric and gynaecology*. 2025.
24. WHO. Endometriosis: world health organization fact-sheets. 2025. available online at <https://www.who.int/news-room/fact-sheets/detail/endometriosis>.
25. Li *et al.* Global and regional trends in the burden of surgically confirmed endometriosis from 1990 to 2021. *reproductive biology and endocrinology*. 2025.
26. B. Puspasari *et al.* Karakteristik pasien endometriosis di rumah sakit dr. cipto manginkusumo. *majalah obstetri ginekologi indonesia*. 2007.
27. Tifani N. Karakteristik Endometriosis di RSUP dr. M. Djamil Padang. *Jurnal Kedokteran Andalas*. 2020.
28. Hidayat *et al.* Karakteristik penderita endometriosis dan adenomiosis di rsup dr. m. djamil padang. *j obgin emas*. 2019.
29. Adilbayeva *et al.* Review: pathogenesis of endometriosis and endometriosis-associated cancers. 2024. *international journal of molecular science*. MDPI. 25,7624.
30. Steinbuch *et al.* Review: endometriosis- associted ovarian cancer: from molecular pathologies to clinical relevance. *international journal of molecular science*. MDPI. 2024. 25,4306.
31. Michael *et al.* Review: endometriosis-associated ovarian cancer: a review of pathogenesis. *international journal of molecular science*. mdpi. 2013. 14.
32. Samartzis *et al.* Endometriosis-Associated Ovarian Carcinoma: Insights into Pathogenesis Diagnostic and Therapeutic Targets-A Narrative Review. *Annal of Translational Medicine*. 2020.
33. Pavaleanu *et al.* Original Article: Immunohistochemical profile of endometriosis- associated ovarian cancer. *research and clinical medicine*. 2018. volume ii, issue II.
34. Markov *et al.* Original Article: Expression of hif-1 α , ki67, sma and e-cadherin in endometriosis, endometrial and ovarian carcinoma. *folia medica*. 2024. vol.66, No.1.
35. Lawrence MD *et al.* Two-Tier system grading system for ovarian epithelial cancer. *the american journal of surgical pathology*. 2007.
36. Gadduci *et al.* Clear cell carcinoma of the ovary: epidemiology, pathological and biological features, treatment options and clinical outcomes. *gynecologic oncology*. elsevier. 2021.

37. Suzuki *et al.* association of the hypoxia-inducible factor-1 α (hif-1 α) gene polymorphisms with prognosis in ovarian clear cell carcinoma. journal of ovarian research. 2019.
38. Barreta *et al.* Endometriosis-associated ovarian cancer population characteristics and prognosis. international journal of gynecological cancer. 2018. vol 28, No 7.
39. Suhatno *et al.* Pedoman nasional pelayanan kedokteran kanker ginekologi. himpunan onkologi ginekologi indonesia. 2018.
40. Liu *et al.* Research: Hypoxia-inducible factor-1 α Promotes Endometrial Stromal Cells Migration and Invasion by Upregulating Autophagy in Endometriosis. Journal Society for Reproduction and Fertility. 2017.1741-7899.
41. Hasby *et al.* Penelitian: Ekspresi Hypoxia Inducible Factor-1 α pada Jaringan Endometriosis. Jurnal Kedokteran Universitas Sumatera Utara. 2015.
42. Qannita *et al.* targeting hypoxia-inducible factor-1 (hif-1) in cancer: emerging therapeutic strategies and pathway regulation. pharmaceuticals. 2024.
43. Zhang *et al.* Systematic and comprehensive insights into hif-1 stabilization under normoxic conditions: implications for cellular adaptation and therapeutic strategies in cancer. review. cellular and molecular biology. 2025.
44. Basheeruddin *et al.* Hypoxia- inducible facotr 1 -alpha (hif-1 α): an essential regulator in cellular metabolic control. cureus. 2024.
45. Yamamoto *et al.* PIK3CA mutation and loss of arid1a protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. virchow archiv. 2011.
46. Ono, Motoki *et al.* Establishment of A Novel Model of Endometriosis-Associated Ovarian Cancer by Transplanting Uterine Tissue from ARID1A/PTEN knockout mice. Scientific Reports, Nature. 2023
47. Molecular Interplay Between PTEN, ARID1A, PD-L1 in Asian Ovarian Clear Cell Carcinoma:Implication for Immunotherapy Response and Patient Stratification. International Journal of Molecular Sciences. 2025.
48. Pejovic, Tanja *et al.* Genetic links between endometriosis and endometriosis associated ovarian cancer-a narrative review (endometriosis-associated cancer). Life MDPI. 2024.
49. Yachida, Nozomi *et al.* ARID1A protein expression is retained in ovarian endometriosis with arid1a loss of function. scientific reports. 2020.
50. Pavaleanu *et al.* Immunohistochemical profile of endometriosis-associated ovarian carcinoma. original article. research and clinical medicine. 2018. vol ii issue ii.
51. Mikhaleva *et al.* Malignant transformation and associated biomarkers of ovarian endometriosis: a narrative review. dvance in therapy, springer. 2020.
52. Kato *et al.* Expression of hepatocyte nuclear factor-1 beta (hnf-1beta) in clear cell tumors and endometriosis of the ovary. modern pathology. 2006.
53. Lestari *et al.* Tinjauan Pustaka: Hipoxia-Inducible Factor-1 (HIF-1) dan Angiogenesis Tumor: Mekanisme, Implikasi Klinis, dan Potensi Terapi. Jurnal Kedokteran Sains dan Teknologi Medik. 2025. Volume VIII No II.

54. Modugno F, Edwards RP. Ovarian cancer: prevention, detection, and treatment of the disease and its recurrence. molecular mechanisms and personalized medicine meeting report. *int j gynecol cancer* [internet]. 2012;22(8):s45-57. available from: <http://europepmc.org/abstract/MED/23013733>
55. Arora, Taruna; Mullangi Sanjana; Reddy Lekkala M. Ovarian Cancer - StatPearls - NCBI Bookshelf [Internet]. 2021. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK567760/>
56. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. *Cancer Res.* 1989 Dec;49(23):6449–65
57. Wang X, Du Z, Xu T, Wang X, Li W, Gao J, et al. HIF-1 α is a rational target for future ovarian cancer therapies. *front oncol.* 2021;11(december):1–15
58. Liu Z, Wu Z, Fan Y, Fang Y. An overview of biological research on hypoxia-inducible factors (HIFs). *Endokrynol Pol.* 2020;71(5):432–40.
59. Harris AL. Hypoxia - A key regulatory factor in tumour growth. *Nature Reviews Cancer.* 2002.
60. Birner P, Schindl M, Obermair A, Plank C, Breiteneker G, Oberhuber G. Overexpression of Hypoxia-inducible Factor 1 α Is a Marker for an Unfavorable Prognosis in Early-Stage Invasive Cervical Cancer1. *Cancer Res.* 2000 Sep 1;60(17):4693–6
61. Cheng JC, Klausen C, Leung PCK. Hypoxia-inducible factor 1 alpha mediates epidermal growth factor-induced down-regulation of E-cadherin expression and cell invasion in human ovarian cancer cells. *Cancer Lett* [Internet]. 2013;329(2):197–206.
62. Daponte A, Ioannou M, Mylonis I, Simos G, Minas M, Messinis IE, et al. Prognostic significance of hypoxia-inducible factor 1 alpha (HIF-1alpha) expression in serous ovarian cancer: An immunohistochemical study. *BMC Cancer.* 2008.
63. Silver DL, Naora H, Liu J, Cheng W, Montell DJ. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. *Cancer Res.* 2004 May;64(10):3550–8
64. He et al. Research: predictive factors of ovarian carcinoma for women with endometrioma aged 45 years and older in China. *Journal of Ovarian Research.* 2017.
65. Aimagambetova et al. Epidemiology of endometrium Kazakhstan: a natural population based cohort analysis (2014-2019) using data from the national health care system. 2025.
66. Aryani et al. Karakteristik faktor risiko penderita endometriosis di RSI Sultan Agung Semarang. Mahesa: Malahayati Student Journal. 2025.
67. Asther *et al.* WHO classification of tumours online. female genital tumours (5th edition). endometriosis and related conditions// endometriosis and derived tumours. international agency for research on cancer. 2025.
68. Huang *et al.* Worldwide burden, risk factors, and temporal trends of ovarian cancer: a global study. *cancers.* 2022.
69. Cabasag *et al.* ovarian cancer today and tomorrow: a global assessment by world region and human development index using globocan 2020. *int j cancer.* 2022.
70. Li *et al.* Global status and attributable risk factors of breast, cervical,

- ovarian, and uterine cancers from 1990 to 2021. *journal of hematology and oncology*. 2025.
71. Bray *et al.* Global cancer statistic 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 18 countries. *ca cancer j clin*. 2024.
 72. Budiana *et al.* Ovarian cancer: pathogenesis and current recommendations for prophylactic surgery. *j turks ger gynecol assoc*. 2019.
 73. Kemenkes RI. rencana kanker nasional 2024-2034: strategi indonesia dalam upaya melawan kanker. kementerian kesehatan republik indonesia. 2024.
 74. Badan Registrasi Kanker Perhimpunan Dokter Spesialis Patologi Anatomi. Kanker di indonesia tahun 2011 data histopatologik, direktorat jendral pelayanan medik departemen kesehatan ri, jakarta, yayasan kanker indonesia. 2011.
 75. Engin *et al.* Endometriosis and adenomiosis: global perspective across the lifespan. *springer*. 2022.
 76. IJ Rowlands *et al.* Global epidemiological data on endometriosis. *springer nature link*. 2022.
 77. WHO. Endometriosis: world health organization fact-sheets. available online at <https://www.who.int/news-room/fact-sheets/detail/endometriosis>. 2025.
 78. Rahmioglu *et al.* Endometriosis: disease mechanism and health disparities. *bulletin of the WHO*. 2024.
 79. Wikipedia. HIF1A. Wikipedia the free encyclopaedia. 2025. available at https://en.wikipedia.org/wiki/hif1a?utm_source=chatgpt.com
 80. Dai *et al.* Hypoxia and the endometrium: an indispensable role for hif-1 α as theurapeutic strategies. *redox biology*. *elsevier*. 2024.
 81. Chen *et al.* Advances in research on malignant transformation of endometriosis-associated ovarian cancer. mini review. *frontiers in oncology*. 2024.
 82. Asis *et al.* Research: association hypoxia inducible factors-1 alpha (hif-1 α) levels and epithelial ovarian cancer (eoc). *indonesian journal of obstetric and gynecology science*. makassar. 2023. volume 6 nomor 1.
 83. Lee *et al.* Over expression of hypoxia-inducible factor 1-alpha in ovarian clear cell carcinoma. *gynecologic oncologic*. 2007. p311-317.
 84. Varga *et al.* Research: predictive factors of endometriosis progression into ovarian cancer. *journal of ovarian research*. 2022. 15:5.

85. Andreou *et al.* Prognostic factors influencing survival in ovarian cancer patients: a 10-year retrospective study. *cancers*. 2023
86. Chen *et al.* Review: new insights about endometriosis- associated ovarian cancer: pathogenesis, risk factors, prediction and diagnosis and treatment. *frontiers in oncology*. 2024.
87. Hablase *et al.* The “road” to malignant transformation from endometriosis to endometriosis-associated ovarian cancer (eaocs): an mtor-centred review. *cancers*. MDPI. 2024.
88. WHO. Female genital tumours. who classifications of tumours 5th edition. international agency for research on cancer. 2020. volume 4.
89. Priyanto *et al.* Analysis of the malignancy risk of endometriosis and ovarian cancer related to endometriosis-associated ovarian cancer: a histopathological review and genetic mutation. research article. *journal of south asian federation of obstetric and gynaecology*. 2025.
90. WHO. Endometriosis: world health organization fact-sheets. 2025. available online at <https://www.who.int/news-room/fact-sheets/detail/endometriosis>.
91. Li *et al.* Global and regional trends in the burden of surgically confirmed endometriosis from 1990 to 2021. *reproductive biology and endocrinology*. 2025.
92. B. Puspasari *et al.* Karakteristik pasien endometriosis di rumah sakit dr. cipto manginkusumo. *majalah obstetri ginekologi indonesia*. 2007.
93. Tifani N. Karakteristik Endometriosis di RSUP dr. M. Djamil Padang. *Jurnal Kedokteran Andalas*. 2020.
94. Hidayat *et al.* Karakteristik penderita endometriosis dan adenomiosis di rsup dr. m. djamil padang. *j obgin emas*. 2019.
95. Adilbayeva *et al.* Review: pathogenesis of endometriosis and endometriosis-associated cancers. 2024. *international journal of molecular science*. MDPI. 25,7624.
96. Steinbuch *et al.* Review: endometriosis- associted ovarian cancer: from molecular pathologies to clinical relevance. *international journal of molecular science*. MDPI. 2024. 25,4306.
97. Michael *et al.* Review: endometriosis-associated ovarian cancer: a review of pathogenesis. *international journal of molecular science*. mdpi. 2013. 14.
98. Samartzis *et al.* Endometriosis-Associated Ovarian Carcinoma: Insights into Pathogenesis Diagnostic and Therapeutic Targets-A Narrative Review. *Annal of Translational Medicine*. 2020.
99. Pavaleanu *et al.* Original Article: Immunohistochemical profile of endometriosis- associated ovarian cancer. *research and clinical medicine*. 2018. volume ii, issue II.
100. Markov *et al.* Original Article: Expression of hif-1 α , ki67, sma and e-cadherin in endometriosis, endometrial and ovarian carcinoma. *folia medica*. 2024. vol.66, No.1.
101. Lawrence MD *et al.* Two-Tier system grading system for ovarian epithelial cancer. *the american journal of surgical pathology*. 2007.
102. Gadduci *et al.* Clear cell carcinoma of the ovary: epidemiology, pathological and biological features, treatment options and clinical outcomes. *gynecologic oncology*. elsevier. 2021.

103. Suzuki *et al.* association of the hypoxia-inducible factor-1 α (hif-1 α) gene polymorphisms with prognosis in ovarian clear cell carcinoma. journal of ovarian research. 2019.
104. Barreta *et al.* Endometriosis-associated ovarian cancer population characteristics and prognosis. international journal of gynecological cancer. 2018. vol 28, No 7.
105. Suhatno *et al.* Pedoman nasional pelayanan kedokteran kanker ginekologi. himpunan onkologi ginekologi indonesia. 2018.
106. Liu *et al.* Research: Hypoxia-inducible factor-1 α Promotes Endometrial Stromal Cells Migration and Invasion by Upregulating Autophagy in Endometriosis. Journal Society for Reproduction and Fertility. 2017.1741-7899.
107. Hasby *et al.* Penelitian: Ekspresi Hypoxia Inducible Factor-1 α pada Jaringan Endometriosis. Jurnal Kedokteran Universitas Sumatera Utara. 2015.
108. Qannita *et al.* targeting hypoxia-inducible factor-1 (hif-1) in cancer: emerging therapeutic strategies and pathway regulation. pharmaceuticals. 2024.
109. Zhang *et al.* Systematic and comprehensive insights into hif-1 stabilization under normoxic conditions: implications for cellular adaptation and therapeutic strategies in cancer. review. cellular and molecular biology. 2025.
110. Basheeruddin *et al.* Hypoxia- inducible facotr 1 -alpha (hif-1 α): an essential regulator in cellular metabolic control. cureus. 2024.
111. Yamamoto *et al.* PIK3CA mutation and loss of arid1a protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. virchow archiv. 2011.
112. Ono, Motoki *et al.* Establishment of A Novel Model of Endometriosis-Associated Ovarian Cancer by Transplanting Uterine Tissue from ARID1A/PTEN knockout mice. Scientific Reports, Nature. 2023
113. Molecular Interplay Between PTEN, ARID1A, PD-L1 in Asian Ovarian Clear Cell Carcinoma:Implication for Immunotherapy Response and Patient Stratification. International Journal of Molecular Sciences. 2025.
114. Pejovic, Tanja *et al.* Genetic links between endometriosis and endometriosis associated ovarian cancer-a narrative review (endometriosis-associated cancer). Life MDPI. 2024.
115. Yachida, Nozomi et al. ARID1A protein expression is retained in ovarian endometriosis with arid1a loss of function. scientific reports. 2020.
116. Pavaleanu *et al.* Immunohistochemical profile of endometriosis-associated ovarian carcinoma. original article. research and clinical medicine. 2018. vol ii issue ii.
117. Mikhaleva *et al.* Malignant transformation and associated biomarkers of ovarian endometriosis: a narrative review. dvance in therapy, springer. 2020.
118. Kato *et al.* Expression of hepatocyte nuclear factor-1 beta (hnf-1beta) in clear cell tumors and endometriosis of the ovary. modern pathology. 2006.
119. Lestari *et al.* Tinjauan Pustaka: Hipoxia-Inducible Factor-1 (HIF-1) dan Angiogenesis Tumor: Mekanisme, Implikasi Klinis, dan Potensi Terapi. Jurnal Kedokteran Sains dan Teknologi Medik. 2025. Volume VIII No II.

120. Modugno F, Edwards RP. Ovarian cancer: prevention, detection, and treatment of the disease and its recurrence. molecular mechanisms and personalized medicine meeting report. *int j gynecol cancer* [internet]. 2012;22(8):s45-57. available from: <http://europepmc.org/abstract/MED/23013733>
121. Arora, Taruna; Mullangi Sanjana; Reddy Lekkala M. Ovarian Cancer - StatPearls - NCBI Bookshelf [Internet]. 2021. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK567760/>
122. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. *Cancer Res.* 1989 Dec;49(23):6449–65
123. Wang X, Du Z, Xu T, Wang X, Li W, Gao J, et al. HIF-1 α is a rational target for future ovarian cancer therapies. *front oncol.* 2021;11(december):1–15
124. Liu Z, Wu Z, Fan Y, Fang Y. An overview of biological research on hypoxia- inducible factors (HIFs). *Endokrynol Pol.* 2020;71(5):432–40.
125. Harris AL. Hypoxia - A key regulatory factor in tumour growth. *Nature Reviews Cancer.* 2002.
126. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of Hypoxia-inducible Factor 1 α Is a Marker for an Unfavorable Prognosis in Early-Stage Invasive Cervical Cancer1. *Cancer Res.* 2000 Sep 1;60(17):4693–6
127. Cheng JC, Klausen C, Leung PCK. Hypoxia-inducible factor 1 alpha mediates epidermal growth factor-induced down-regulation of E-cadherin expression and cell invasion in human ovarian cancer cells. *Cancer Lett* [Internet]. 2013;329(2):197–206.
128. Daponte A, Ioannou M, Mylonis I, Simos G, Minas M, Messinis IE, et al. Prognostic significance of hypoxia-inducible factor 1 alpha (HIF-1alpha) expression in serous ovarian cancer: An immunohistochemical study. *BMC Cancer.* 2008.
129. Silver DL, Naora H, Liu J, Cheng W, Montell DJ. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. *Cancer Res.* 2004 May;64(10):3550–8
130. He et al. Research: predictive factors of ovarian carcinoma for women with endometrioma aged 45 years and older in China. *Journal of Ovarian Research.* 2017.
131. Aimagambetova et al. Epidemiology of endometrium Kazakhstan: a natural population based cohort analysis (2014-2019) using data from the national health care system. 2025.
132. Aryani et al. Karakteristik faktor risiko penderita endometriosis di RSI Sultan Agung Semarang. *Mahesa: Malahayati Student Journal.* 2025.
133. Pramesti et al. Karakteristik klinikopatologis penderita endometriosis di RSUP Sanglah Denpasar. *Jurnal Medika Udayana.* 2020.
134. Sanglah Denpasar. *Jurnal Medika Udayana.* 2020.

